MX2024003655A - Metodos para tratar cancer. - Google Patents
Metodos para tratar cancer.Info
- Publication number
- MX2024003655A MX2024003655A MX2024003655A MX2024003655A MX2024003655A MX 2024003655 A MX2024003655 A MX 2024003655A MX 2024003655 A MX2024003655 A MX 2024003655A MX 2024003655 A MX2024003655 A MX 2024003655A MX 2024003655 A MX2024003655 A MX 2024003655A
- Authority
- MX
- Mexico
- Prior art keywords
- treating cancer
- methods
- mpn
- formula
- therapeutic methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 abstract 3
- 208000032027 Essential Thrombocythemia Diseases 0.000 abstract 2
- 208000017733 acquired polycythemia vera Diseases 0.000 abstract 2
- 208000037244 polycythemia vera Diseases 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 229940083338 MDM2 inhibitor Drugs 0.000 abstract 1
- 239000012819 MDM2-Inhibitor Substances 0.000 abstract 1
- 206010028537 myelofibrosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000003476 primary myelofibrosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen métodos terapéuticos y composiciones farmacéuticas para tratar cáncer incluido un neoplasma mieloproliferativo (MPN), incluido policitemia vera (PV), trombocitemia esencial (ET), y mielofibrosis primaria en un sujeto humano. En ciertas modalidades, la invención incluye métodos terapéuticos para tratar una MPN utilizando un inhibidor de MDM2 de la Fórmula (I) o Fórmula (II).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664673P | 2018-04-30 | 2018-04-30 | |
| US201862701088P | 2018-07-20 | 2018-07-20 | |
| US201862781942P | 2018-12-19 | 2018-12-19 | |
| US201962834848P | 2019-04-16 | 2019-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003655A true MX2024003655A (es) | 2024-04-15 |
Family
ID=68386769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011608A MX2020011608A (es) | 2018-04-30 | 2019-04-30 | Metodos para tratar cancer. |
| MX2024003655A MX2024003655A (es) | 2018-04-30 | 2020-10-30 | Metodos para tratar cancer. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011608A MX2020011608A (es) | 2018-04-30 | 2019-04-30 | Metodos para tratar cancer. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12115153B2 (es) |
| EP (1) | EP3787625A4 (es) |
| JP (2) | JP2021523220A (es) |
| KR (1) | KR20210019422A (es) |
| CN (1) | CN112512525A (es) |
| AU (1) | AU2019263064A1 (es) |
| BR (1) | BR112020022148A2 (es) |
| CA (1) | CA3098606A1 (es) |
| CL (1) | CL2020002833A1 (es) |
| CO (1) | CO2020014599A2 (es) |
| CR (1) | CR20200576A (es) |
| IL (2) | IL278345B2 (es) |
| JO (1) | JOP20200273A1 (es) |
| MX (2) | MX2020011608A (es) |
| PE (1) | PE20211653A1 (es) |
| PH (1) | PH12020551820A1 (es) |
| SG (1) | SG11202010793UA (es) |
| TN (1) | TN2020000210A1 (es) |
| TW (2) | TW202146387A (es) |
| WO (1) | WO2019213074A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114450008A (zh) * | 2019-09-16 | 2022-05-06 | 诺华股份有限公司 | Mdm2抑制剂用于治疗骨髓纤维化的用途 |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| WO2021175192A1 (en) * | 2020-03-02 | 2021-09-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Treatment methods and biomarkers for mdm2 inhibitors |
| WO2022219128A1 (en) * | 2021-04-15 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | In vitro tests allowing to identify the potential for mdm2 inhibitors to induce the selection of mutations in patients suffering from a myeloproliferative neoplasm |
| WO2023039160A1 (en) * | 2021-09-09 | 2023-03-16 | Kartos Therapeutics | Methods of treating a cancer overexpressing one or more bcl-2 family proteins |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| MA38193B1 (fr) * | 2012-12-07 | 2018-12-31 | Geron Corp | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives |
| MX368703B (es) | 2013-02-28 | 2019-10-11 | Amgen Inc | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. |
| JOP20200296A1 (ar) * | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| MA39094B1 (fr) * | 2013-11-11 | 2020-06-30 | Amgen Inc | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers |
| AU2014354769A1 (en) * | 2013-11-26 | 2016-05-26 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| AU2014372167A1 (en) * | 2013-12-23 | 2016-06-09 | Novartis Ag | Pharmaceutical combinations |
| RU2716256C2 (ru) | 2014-01-28 | 2020-03-11 | Бак Инститьют Фо Ресеч Он Эйджинг | Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением |
| TW201613576A (en) * | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
-
2019
- 2019-04-30 IL IL278345A patent/IL278345B2/en unknown
- 2019-04-30 SG SG11202010793UA patent/SG11202010793UA/en unknown
- 2019-04-30 KR KR1020207034245A patent/KR20210019422A/ko not_active Application Discontinuation
- 2019-04-30 TW TW110132121A patent/TW202146387A/zh unknown
- 2019-04-30 CN CN201980043405.4A patent/CN112512525A/zh active Pending
- 2019-04-30 AU AU2019263064A patent/AU2019263064A1/en active Pending
- 2019-04-30 TN TNP/2020/000210A patent/TN2020000210A1/en unknown
- 2019-04-30 JO JOP/2020/0273A patent/JOP20200273A1/ar unknown
- 2019-04-30 WO PCT/US2019/029906 patent/WO2019213074A1/en unknown
- 2019-04-30 US US17/052,040 patent/US12115153B2/en active Active
- 2019-04-30 BR BR112020022148-1A patent/BR112020022148A2/pt unknown
- 2019-04-30 CA CA3098606A patent/CA3098606A1/en active Pending
- 2019-04-30 MX MX2020011608A patent/MX2020011608A/es unknown
- 2019-04-30 CR CR20200576A patent/CR20200576A/es unknown
- 2019-04-30 PE PE2020001785A patent/PE20211653A1/es unknown
- 2019-04-30 JP JP2021510264A patent/JP2021523220A/ja active Pending
- 2019-04-30 TW TW108115047A patent/TWI741286B/zh active
- 2019-04-30 IL IL308399A patent/IL308399A/en unknown
- 2019-04-30 EP EP19796292.1A patent/EP3787625A4/en active Pending
-
2020
- 2020-10-30 PH PH12020551820A patent/PH12020551820A1/en unknown
- 2020-10-30 MX MX2024003655A patent/MX2024003655A/es unknown
- 2020-10-30 CL CL2020002833A patent/CL2020002833A1/es unknown
- 2020-11-25 CO CONC2020/0014599A patent/CO2020014599A2/es unknown
-
2024
- 2024-01-24 JP JP2024008582A patent/JP2024050668A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020002833A1 (es) | 2021-04-30 |
| CR20200576A (es) | 2021-04-30 |
| CO2020014599A2 (es) | 2021-02-26 |
| JOP20200273A1 (ar) | 2020-11-01 |
| IL308399A (en) | 2024-01-01 |
| TWI741286B (zh) | 2021-10-01 |
| AU2019263064A1 (en) | 2020-12-03 |
| PE20211653A1 (es) | 2021-08-24 |
| TW202146387A (zh) | 2021-12-16 |
| BR112020022148A2 (pt) | 2021-04-13 |
| CA3098606A1 (en) | 2019-11-07 |
| PH12020551820A1 (en) | 2021-07-26 |
| IL278345A (es) | 2020-12-31 |
| KR20210019422A (ko) | 2021-02-22 |
| JP2024050668A (ja) | 2024-04-10 |
| US20210186946A1 (en) | 2021-06-24 |
| IL278345B1 (en) | 2024-01-01 |
| EP3787625A4 (en) | 2022-01-26 |
| US12115153B2 (en) | 2024-10-15 |
| SG11202010793UA (en) | 2020-11-27 |
| WO2019213074A1 (en) | 2019-11-07 |
| EP3787625A1 (en) | 2021-03-10 |
| JP2021523220A (ja) | 2021-09-02 |
| IL278345B2 (en) | 2024-05-01 |
| TN2020000210A1 (en) | 2022-07-01 |
| MX2020011608A (es) | 2021-02-17 |
| CN112512525A (zh) | 2021-03-16 |
| TW201945340A (zh) | 2019-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551820A1 (en) | Methods of treating cancer | |
| CR20220070A (es) | Inhibidores de parp1 | |
| PH12016500871A1 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2021007773A (es) | Compuestos inhibidores de egfr. | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| GEP20237519B (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| CO2020015923A2 (es) | Antagonista de gremlin-1 para la prevención y tratamiento del cáncer | |
| MX2021015628A (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. | |
| PH12020552059A1 (en) | Dosing regimen for the treatment of pi3k related disorders | |
| MX2020012503A (es) | Métodos de tratamiento de neoplasias mieloproliferativas. | |
| EP4275761A3 (en) | Alkaline phosphatase agents for treatment of radiation disorders | |
| CR20220374A (es) | Métodos de tratamiento de la esplenomegalia | |
| MX2020000402A (es) | Nuevos derivados de xantina sustituidos. | |
| MX2022005358A (es) | Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso. | |
| BR112016016901A2 (pt) | agentes para o uso no tratamento de inflamação retinal | |
| MX2020005342A (es) | Compuestos de pirazolopiridinona. | |
| MX2020005344A (es) | Compuestos de pirazolopiridinona. | |
| PH12018500450A1 (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| MX2022007516A (es) | Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos. | |
| EA202092550A1 (ru) | Способы лечения рака | |
| MX2023015097A (es) | Tratamiento de sintomas asociados a neoplasias mieloproliferativas. | |
| TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2020010673A (es) | Formulaciones de apixaban. |